[1]Patent:US2008/58518,2008,A1.Locationinpatent:Page/Pagecolumn14-15
[2]ACSMedicinalChemistryLetters,2010,vol.1,p.204-208
[1]Locationinpatent:experimentalpartLavey,C.Flader;Hesk;Koharski;Truong;McNamara[Journaloflabelledcompoundsandradiopharmaceuticals,2011,vol.54,#4,p.196-201]
[1]CurrentPatentAssignee:FUNDSTEPBYSTEP;FUNDACIONDELACOMUNIDADVALENCIANACENTRODEINVESTIGPRINCIPEFELIPE-WO2020/193802,2020,A1Locationinpatent:Page/Pagecolumn52
[1]CurrentPatentAssignee:FUNDSTEPBYSTEP;FUNDACIONDELACOMUNIDADVALENCIANACENTRODEINVESTIGPRINCIPEFELIPE-WO2020/193802,2020,A1
[1]CurrentPatentAssignee:FUNDSTEPBYSTEP;FUNDACIONDELACOMUNIDADVALENCIANACENTRODEINVESTIGPRINCIPEFELIPE-WO2020/193802,2020,A1
Title: Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile.
Journal: Archives of toxicology 20180710
Title: CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Journal: Cell reports 20161122
Title: Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
Journal: Scientific reports 20160101
Title: Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains.
Journal: ACS chemical biology 20131115
Title: A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Journal: Cancer biology & therapy 20130701
Title: The requirement for cyclin D function in tumor maintenance.
Journal: Cancer cell 20121016
Title: Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.
Journal: Cancer cell 20121016
Title: Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.
Journal: Cell cycle (Georgetown, Tex.) 20120715
Title: Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
Journal: Cancer biology & therapy 20111001
Title: Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
Journal: Cancer biology & therapy 20110815
Title: Establishing the carbon skeleton of pharmaceutical agents using HSQC-ADEQUATE spectra.
Journal: Journal of pharmaceutical and biomedical analysis 20110715
Title: The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells.
Journal: Molecular cancer therapeutics 20110601
Title: Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
Journal: Molecular cancer therapeutics 20110401
Title: Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma.
Journal: Cell cycle (Georgetown, Tex.) 20110315
Title: Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.
Journal: Molecular cancer therapeutics 20100801
Title: A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.
Journal: Cancer cell 20100713
Title: The landscape of somatic copy-number alteration across human cancers.
Journal: Nature 20100218
Title: Parry D, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010 Aug;9(8):2344-53.
Title: Feldmann G, et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther. 2011 Oct 1;12(7):598-609.
